Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Darbepoetin Alfa (Aranesp) Industry?

The market size for darbepoetin alfa (aranesp) has seen consistent growth in recent times. The market is expected to expand from $5.81 billion in 2024 to approximately $6.06 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.2%. The growth observed in the historic period can be accounted for by factors such as advancements in the treatment of anemia, the demand for erythropoiesis-stimulating agents (ESAs), innovation in biopharmaceuticals, widely accepted clinical treatments, and enhanced patient outcomes.

In the coming years, the market size of darbepoetin alfa (aranesp) is predicted to witness substantial growth, escalating to $7.37 billion by 2029 with a compound annual growth rate (CAGR) of 5.0%. Factors such as healthcare reimbursement policies, enhanced awareness and education, improvements in healthcare infrastructure, demands for renal care, and an aging population contribute to growth in the forecast period. A few significant trends in the forecast period comprise global market expansion, the integration of digital health, tailored treatment methodologies, the acceptance of biosimilars, and the use of long-acting formulations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12171&type=smp

#Which Factors Are Currently Driving The Growth Of The Darbepoetin Alfa (Aranesp) Market?

The darbepoetin alfa market is expected to expand due to the rising prevalence of chronic diseases. Chronic ailments, which last for more than three months and may worsen over time, use darbepoetin alfa for treatment and to reverse anemia induced by chemotherapy in cancer patients. For example, the Australian Institute of Health and Welfare reported in June 2024, that chronic conditions caused 171,500 fatalities in 2022, equating to 90% of all deaths, at a rate of 659 per 100,000 population. The age-standardised mortality rate from chronic ailments dropped to 448 per 100,000 in 2020, but grew to 459 in 2021 and 490 in 2022. Consequently, the rise in chronic disease occurrence is fuelling the darbepoetin alfa market’s growth.

How Is The Global Darbepoetin Alfa (Aranesp) Market Structured In Terms Of Segments?

The darbepoetin alfa (aranesp) market covered in this report is segmented –

1) By Type: Epogen, Procrit, Aranesp, Other Types

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Patients With Chronic Kidney Disease, Patients With Cancer, Other Applications

Subsegments:

1) By Epogen: Standard Formulations, Enhanced Formulations

2) By Procrit: Standard Formulations, Biosimilars

3) By Aranesp: Single-Dose Vials, Multi-Dose Vials

4) By Other Types: Combination Therapies, Alternative Erythropoiesis-Stimulating Agents

What Trends Are Currently Influencing Growth In The Darbepoetin Alfa (Aranesp) Market?

The emergence of innovative products is a significant trend being witnessed in the darbepoetin alfa industry. To stay competitive, major entities in the darbepoetin alfa market are leveraging new technologies. For instance, GlaxoSmithKline. Ltd., a pharmaceutical and biotechnology firm based in the UK, launched Jesduvroq (daprodustat) in February 2023, with approval from the US Food and Drug Administration (FDA). Daprodustat or darbepoetin alfa, also known as recombinant human erythropoietin (rhEPO), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. This medical innovation is used for daily treatment of anemia caused by chronic kidney disease (CKD) in patients who have undergone dialysis for a minimum of four months.

Who Are The Main Participants Shaping The Darbepoetin Alfa (Aranesp) Market Landscape?

Major companies operating in the darbepoetin alfa (aranesp) market include Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/darbepoetin-alfa-aranesp-global-market-report

Which Region Currently Holds The Largest Share In The Darbepoetin Alfa (Aranesp) Market?

North America was the largest region in the darbepoetin alfa (Aranesp) market in 2024. The regions covered in the darbepoetin alfa (Aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12171&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model